The ReadoutAnother shakeup at Moderna, biotech’s destructive potential, & why diabetes R&D is hard By Damian Garde and Meghana Keshavan Feb. 21, 2017 Reprints The Readout for February 21, 2017 About the Authors Reprints Damian Garde National Biotech Reporter Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast. [email protected] @damiangarde Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. [email protected] @megkesh
The Readout Meghana Keshavan Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
The Readout Damian Garde Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
The Readout Damian Garde Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain
The Readout Damian Garde How Biogen got Aduhelm approved, Sanofi’s future in mRNA, & Celgene’s endless saga
The Readout Meghana Keshavan Aduhelm’s impact on Medicare, a new CRISPR therapy, & a Warp Speed retirement
